SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/22/2017 9:48:37 AM - Followers: 60 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2674   runners to your mark...........s--e-----t................. heavymetal 03/22/17 09:48:36 AM
#2673   I haven't said much at all in over Naamplao 03/21/17 06:13:02 PM
#2672   Ya know gene... I was almost certain I 123414 03/21/17 04:32:42 PM
#2671   We have enough cash to get us to 123414 03/21/17 04:28:13 PM
#2670   How we know the strategy isn't not to CUIN2 03/21/17 04:12:39 PM
#2669   nice pop in the end. Wouldn't feel sad Gene_Simmons 03/21/17 04:05:05 PM
#2668   Lol, just the stability. suerte88 03/21/17 01:32:02 PM
#2667   News out. Gene_Simmons 03/15/17 08:57:27 AM
#2666   The guy is a nuisance. Geo2014 03/09/17 10:10:07 AM
#2665   Thanks Geo for backing me up ! suerte88 03/09/17 01:39:14 AM
#2664   There are two scenarios when a subject is Geo2014 03/08/17 11:20:56 PM
#2663   Read my post again... I said "As Geo2014 03/08/17 11:18:27 PM
#2662   We can confirm they are recruiting. 123414 03/08/17 05:24:37 PM
#2661   You can confirm what? A screening subject Geo2014 03/08/17 04:50:58 PM
#2660   We can confirm they are... Recruiting for Intravesical 123414 03/06/17 04:59:45 PM
#2659   Updates on enrolment and treatment of candidates will MIKE22CA 03/06/17 09:02:05 AM
#2658   Have they enrolled the first patient for the trial? The Rainmaker 03/06/17 01:42:53 AM
#2657   So when are they going to release their frackus14 02/28/17 12:11:29 PM
#2656   This technology has superconfined toxity to patient. 123414 02/27/17 05:50:22 AM
#2655   Please contact spam police. Send them your 123414 02/27/17 05:29:11 AM
#2654   you only post old stuff, stop spaming!!!! suerte88 02/27/17 02:49:39 AM
#2653   Theralase Research Demonstrates Lead Drug Also Effective for 123414 02/26/17 05:20:11 PM
#2652 CUIN2 02/25/17 11:29:57 PM
#2651   Official title 1b trial vs Offical title 2/3 123414 02/24/17 06:13:50 AM
#2650   A look into the pipeline. 123414 02/20/17 05:00:10 PM
#2649   Agreed 100% with you... I have put that Naamplao 02/18/17 10:33:03 PM
#2648   Precise conclusions should be drawn from the protocol. Geo2014 02/18/17 10:26:38 PM
#2647   It is in the focus. EOM 123414 02/18/17 07:54:10 PM
#2646   That does not rule out that the lower 123414 02/18/17 07:52:06 PM
#2645   That is the a low priority focus not Naamplao 02/18/17 07:26:12 PM
#2644   This IS NOT what is said in that document. Naamplao 02/18/17 07:16:23 PM
#2643   Other measures for the first three. 123414 02/18/17 06:29:20 PM
#2642   EXACTLY and THANK YOU!!!!!! Geo2014 02/18/17 06:21:39 PM
#2641   a low dose which is the therapeutic dose. 123414 02/18/17 06:21:28 PM
#2640   In an earlier post I showed a post Naamplao 02/18/17 12:52:12 PM
#2639   Maybe some news on the patients for Phase frackus14 02/17/17 05:10:07 PM
#2638   Well a very quiet but interesting charting day Naamplao 02/17/17 04:56:20 PM
#2637   Phase 1 clinical trials are not efficacy trials, Geo2014 02/17/17 12:55:19 PM
#2636 Onthegogo 02/17/17 12:01:33 PM
#2635   I agree with your post here some previous Onthegogo 02/17/17 11:56:37 AM
#2634   Did you see the volume for V. TLT Onthegogo 02/17/17 11:53:32 AM
#2633   Those 2 trades were relatively small volume 100 Naamplao 02/17/17 10:55:52 AM
#2632   There was nothing traded since no one holding Naamplao 02/17/17 10:08:30 AM
#2631   Interesting, 123414 02/16/17 09:28:34 PM
#2630   The stock wasnt open until like 11:35am, this frackus14 02/16/17 05:47:02 PM
#2629   I'm not finding anything suggesting a stock halt? CUIN2 02/16/17 05:30:11 PM
#2628   Why was the trade of the stock halted frackus14 02/16/17 04:59:41 PM
#2627   Dr. Rueck: Where do PDCs best exert their Onthegogo 02/16/17 01:56:07 PM
#2626   Agreed. Naamplao 02/16/17 11:08:56 AM
#2625   Most investors probably think that it is easy Naamplao 02/16/17 11:07:13 AM